Advanced

Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer

Rasmusson, Elisabeth LU ; Gunnlaugsson, Adalsteinn LU ; Kjellén, Elisabeth LU ; Nilsson, Per LU ; Einarsdottir, Margret; Wieslander, Elinore LU ; Fransson, Per LU ; Ahlgen, Göran and Blom, René LU (2016) In Acta Oncologica 55(8). p.1016-1021
Abstract

Background: Low-dose rate brachytherapy (LDR-BT) has been used in Sweden for more than a decade for treatment of low-risk prostate cancer. This study presents the outcome for patients treated with LDR-BT at a single institution with focus on the association between dose and biochemical failure-free survival (BFFS). Methods: In total 195 patients were treated with LDR-BT between 2004 and 2008. The patients were followed systematically for side effects for at least one year. PSA levels were followed regularly from three months and for at least five years. Outcome was analyzed in relation to clinical variables at baseline and to radiotherapy data. Results: Kaplan-Meier estimated BFFS at five years was 95.7%. Dose to the prostate in terms... (More)

Background: Low-dose rate brachytherapy (LDR-BT) has been used in Sweden for more than a decade for treatment of low-risk prostate cancer. This study presents the outcome for patients treated with LDR-BT at a single institution with focus on the association between dose and biochemical failure-free survival (BFFS). Methods: In total 195 patients were treated with LDR-BT between 2004 and 2008. The patients were followed systematically for side effects for at least one year. PSA levels were followed regularly from three months and for at least five years. Outcome was analyzed in relation to clinical variables at baseline and to radiotherapy data. Results: Kaplan-Meier estimated BFFS at five years was 95.7%. Dose to the prostate in terms of D90% was significantly associated with BFFS [HR 0.90 (95%CI 0.83−0.96), p = 0.002]. Conclusion: Out data confirmed that absorbed dose is a predictive factor for BFFS for low-risk patients without androgen deprivation therapy. With our treatment routines and dosimetry, a D90% in the range of 170−180 Gy gives excellent outcomes with acceptable toxicity for patients with low-risk prostate cancer.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
55
issue
8
pages
6 pages
publisher
Taylor & Francis
external identifiers
  • Scopus:84967155322
ISSN
0284-186X
DOI
10.1080/0284186X.2016.1175659
language
English
LU publication?
yes
id
e6328178-de1d-42ca-bf06-1dca262b3a3f
date added to LUP
2016-06-01 13:12:10
date last changed
2016-10-05 12:51:16
@misc{e6328178-de1d-42ca-bf06-1dca262b3a3f,
  abstract     = {<p>Background: Low-dose rate brachytherapy (LDR-BT) has been used in Sweden for more than a decade for treatment of low-risk prostate cancer. This study presents the outcome for patients treated with LDR-BT at a single institution with focus on the association between dose and biochemical failure-free survival (BFFS). Methods: In total 195 patients were treated with LDR-BT between 2004 and 2008. The patients were followed systematically for side effects for at least one year. PSA levels were followed regularly from three months and for at least five years. Outcome was analyzed in relation to clinical variables at baseline and to radiotherapy data. Results: Kaplan-Meier estimated BFFS at five years was 95.7%. Dose to the prostate in terms of D<sub>90%</sub> was significantly associated with BFFS [HR 0.90 (95%CI 0.83−0.96), p = 0.002]. Conclusion: Out data confirmed that absorbed dose is a predictive factor for BFFS for low-risk patients without androgen deprivation therapy. With our treatment routines and dosimetry, a D<sub>90%</sub> in the range of 170−180 Gy gives excellent outcomes with acceptable toxicity for patients with low-risk prostate cancer.</p>},
  author       = {Rasmusson, Elisabeth and Gunnlaugsson, Adalsteinn and Kjellén, Elisabeth and Nilsson, Per and Einarsdottir, Margret and Wieslander, Elinore and Fransson, Per and Ahlgen, Göran and Blom, René},
  issn         = {0284-186X},
  language     = {eng},
  month        = {05},
  number       = {8},
  pages        = {1016--1021},
  publisher    = {ARRAY(0x8cd3e18)},
  series       = {Acta Oncologica},
  title        = {Low-dose rate brachytherapy with I-125 seeds has an excellent 5-year outcome with few side effects in patients with low-risk prostate cancer},
  url          = {http://dx.doi.org/10.1080/0284186X.2016.1175659},
  volume       = {55},
  year         = {2016},
}